

DEA Trends & Update

Honolulu, HI Pharmacy Diversion Awareness Conference



January 22-23, 2017



Thomas W. Prevoznik
Associate Section Chief
Pharmaceutical Investigations
Section
Diversion Control Division



Goals and Objectives

- Public Health Epidemic
- Impact on Society
- Criminal Activity
- The Controlled Substances Act: Checks & Balances
- Drugs of Abuse
- Legal obligations: DEA registrant
- The DEA Response
- Disposal



Public Health Epidemic



U.S. Drug Enforcement Administration
Office of Diversion Control



"Primum non nocere"



On an average Day in the U.S.:



- § More than 650,000 opioid prescriptions dispensed₁
- § **3,900 people** initiate nonmedical use of prescription opioids₂
- § 580 people initiate heroin use2

- 1. Source: IMS Health National Prescription Audit1
- 2. SAMHSA National Survey on Drug Use and Health2
- 3. CDC National Vital Statistics System3



Public Health Epidemic

2000-2015

Over 550,000 unintentional drug overdose deaths in the US

2015

52,404 drug-related overdose deaths

143 deaths every 24 hours (129 in '14)

1 death every 10.07 minutes (11.16 minutes '14)

33,091 deaths involved opioids, including heroin (91) *17,536 deaths involved opioid pain relievers (48)

CDC National Center for Health Statistics/Morbidity and Morality Weekly Report (MMWR); December 30, 2016

^{*}Opioid Pain relievers (other than synthetic opioids) ICD-10 codes (T40.2, T40.3, & T40.6) excluding the category predominated by illicit fentanyl



2014 Comparison

Figure 1. Drug overdose death rates* compared to motor vehicle-related death rates, Hawaii residents, 1999-2014 (Lines show age-adjusted death rates (per 100,000 residents), while actual number of fatalities is indicated by bar and label.)



Source: HAWAII DEPARTMENT OF HEALTH http://health.hawaii.gov/injuryprevention/ Released October, 2015



Opioid Pain Relievers contributed to 35% of Drug Overdose Deaths

Table 1. Drug overdose deaths: Demographic characteristics, Hawaii residents, 2010-2014

		Average annual		Average annual rate
		number	Percent	per 100,000 residents
Gender	Female	51	33%	8.6
	Male	104	67%	16.6
Age (in years)*	15-24	8	5%	4.1
	25-44	53	33%	14.0
	45-54	48	32%	25.8
	55 and older	47	31%	12.1
County of	Hawaii	20	14%	12.0
residence	Honolulu	105	65%	12.2
	Kauai	5	3%	-
	Maui	26	18%	17.5

This document was produced in conjunction with CDC's Core Violence and Injury Prevention Program under Cooperative Agreement 11-1101.


Source: HAWAII DEPARTMENT OF HEALTH http://health.hawaii.gov/injuryprevention/ Released October, 2015

§ Between 2006 -2014: Hawaii's overdose rate has increased 83%---double the national average of 37% during that time period






Opioid involvement in benzodiazepine overdose






Prescription Opiates v. Heroin




U.S. Drug Enforcement Administration Office of Diversion Control

Circle of Addiction & the Next Generation






Scope of the Problem





Overdoses in 2014

Overdose Deaths by Age in 2014 per 100,000 people




Source: CDC

Data: CDC



Everyone is Impacted

Overdose Deaths by Race in 2014 per 100,000 people



Data: CDC

Source: CDC



.DARCARSvolkswagen.com

APedram@darcars.com







'Liaisons Dangereuses'
New approach to classic P. 19



Cooling down



POLITICS

Stalemate on 'cliff' Sides stop talking; Obama's rate hikes may be flexible. P. 13

LOCAL

FRI analyst husted

Heroin use spikes in area suburbs Pill addicts risk deadly drug



Community Impact?

Heroin trafficking organizations relocating to areas where prescription drug abuse is on the rise

Heroin traffickers pave the way for increasing crime and violence

Law enforcement and prosecutors eventually fighting the problem on two fronts (prescription opiate diversion and heroin distribution) further depleting resources

Communities suffer



Violence



U.S. Drug Enforcement Administration Office of Diversion Control



Violence Related to Controlled Substance Pharmaceuticals







The 1960s/70s/80s



Uppers - Amphetamines



Downers - Barbiturates



Quaalude



Hydromorphone



"Ts and Blues"






Meprobamate




Oxycodone/APAP




"Fours and Doors"



Overweight? Suffering from anxiety or erectile dysfunction? Well, relief is just a prescription pill away according to the endless television ads promoting prescription drugs.








The 1990s

OxyContin® Tablets (exycodone hydrochloride controlled-release)





Prescription Drug Abuse is driven by

Indiscriminate Prescribing Criminal Activity



Most Frequent Method of Obtaining a Pharmaceutical Controlled Substance for Non Medical Use

Friends and Family...For Free!!





Patients Often Prescribed Extra Painkillers, Many Share Them

Two new U.S. studies shed light on opioid epidemic

John Hopkins Study:

+60% had leftover opioids they hung on for "future use"

20% shared their medications

8% likely will share w/ friend

14% likely will share w/ relative

-10% securely lock their medication

https://www.nlm.nih.gov/medlineplus/news/fullstory_159336.html

University of Pennsylvania Dental School Study:

More than half of the narcotics prescribed for wisdom teeth removal go unused...findings suggest that more than **100** million pills prescribed go unused...leaving the door open for possible misuse or abuse.

Source: https://www.pennmedicine.org/news/news-releases/2016/september/100-million-prescription-opioi

Survey of Long-Term Painkiller Users

- Majority say their doctor talked about possibility of addiction or dependence – 61% say there was no discussion about plan to get them off.
- Majority say the use the drugs to relieve pain. Other major reasons for taking them:
 - 20% 'for fun or get high"
 - 14% "to deal with day-to-day stress"
 - 10% "ro relax or relieve tension"

Other Findings:

- 34% admit being dependent or addicted
- 17% have taken painkillers that were not specifically prescribed for them
- 14% have given their painkillers to a family member or friend
- 20% know or suspect someone was using, taking or selling their painkillers

Our Youth



U.S. Drug Enforcement Administration
Office of Diversion Control




Where else do our kids get their information from?

www.erowid.org




Where do kids get their information from? www.bluelight.org





Criminal Activity



U.S. Drug Enforcement Administration
Office of Diversion Control



Egregious Activity (Not on the fringes)



United States V. Alvin Yee, M.D.

Dr. Yee primarily met with his "patients" in Starbucks cafes throughout Orange County, California.

He would see up to a dozen patients each night between 7:00 and 11:00 p.m. and wrote these "patients" prescriptions, primarily for opiates, in exchange for cash.

Yee pled guilty to distributing millions of dollars in oxycodone, oxymorphone, hydrocodone, hydromorphone, Adderall® and alprazolam outside the course of professional practice and without a legitimate medical purpose.





United States V. Alvin Yee, M.D.

CURES Data (PMP)

During a one-year time period, Yee wrote prescriptions for a total of 876,222 dosage units of all medications combined.

52% of all prescriptions (458,056 dosage units) written by Yee were for oxycodone (92%-30mg) during the one-year period.

96% - oxycodone, hydrocodone, alprazolam, hydromorphone, and oxymorphone.

Almost half of Yee's patients were 25 and under.





The Controlled Substances Act: Checks & Balances



U.S. Drug Enforcement Administration
Office of Diversion Control



Mission

The mission of the Office of Diversion Control is to prevent, detect, and investigate the diversion of pharmaceutical controlled substances and listed chemicals from legitimate channels of distribution

ensuring an adequate and uninterrupted supply of controlled substances to meet legitimate medical, commercial, and scientific

Enforcement Admi


Office of Diversion Control

while ...

needs.



Closed System of Distribution



• **Practitioners:** 1,253,249

Mid Level Practitioner: 319,280


• Retail Pharmacies: 72,126

Hospital/Clinics: 17,674

U.S. Drug Enforcement Administration Office of Diversion Control



Closed System of Distribution





Closed System of Distribution

The DEA is responsible for:


- o the <u>oversight</u> of the system
- o the **integrity** of the system
- the <u>protection</u> of the public health and safety

Office of Diversion Control

Enforcement



Drugs of Abuse



U.S. Drug Enforcement Administration
Office of Diversion Control



Most commonly prescribed prescription medicine?

Hydrocodone/acetaminophen


Hydrocodone

- Ø Hydrocodone / Acetaminophen (toxicity)
- Ø Similarities:
 - Structurally related to codeine
 - Equal to morphine in producing opiate-like effects
- Ø Brand Names: Vicodin®, Lortab®, Lorcet®
- October 6, 2014 moved to SCHEDULE II
- ∅ "Cocktail" or "Trinity"
 - Ø Hydrocodone
 - Ø Soma ® / carisoprodol



Street prices: \$2 to \$10+ per tablet depending on strength & region

The Trinity








Benzodiazepine

Oxycodone

- § OxyContin controlled release formulation of Schedule II oxycodone
 - The controlled release method of delivery allowed for a longer duration of drug action so it contained much larger doses of oxycodone
 - Abusers easily compromised the controlled release formulation by crushing the tablets for a powerful morphine-like high
 - 10, 15, 20, 30, 40, 60, 80mg available
- § Effects:
 - Similar to morphine in effects and potential for abuse/ dependence
 - Sold in "Cocktails" or the "Holy Trinity"
 - § Oxycodone, Soma ® / Xanax®
- § Street price: Approx. \$80 per 80mg tablet

NOTE: New formulation introduced into the marketplace in 2010 that is more difficult to circumvent for insufflation (snorting) or injection. Does nothing to prevent oral abuse.

Oxycodone HCL CR (OxyContin®) Reformulation






New OxyContin® OP









Oxymorphone Extended Release Opana ER® (Schedule II)

Ø Opana ER® - (Schedule II)

- Treats constant, around the clock, moderate to severe pain
- Becoming popular and is abused in similar fashion to oxycodone; August 2010 (Los Angeles FD TDS)
- Slang: Blues, Mrs. O, Octagons, Stop Signs, Panda Bears
- Street: \$10.00 \$80.00









Hydromorphone








Other Opiates of Interest











U.S. Drug Enforcement Administration
Office of Diversion Control

Methadone- 5mg &10mg





Methadone 40 mg







Legal Obligations: DEA Registrant



U.S. Drug Enforcement Administration
Office of Diversion Control



Effective Controls

- § All applicants and registrants shall provide effective controls and procedures to guard against theft and diversion of controlled substances.
- § In order to determine whether a registrant has provided effective controls against diversion, the Administrator shall use the security requirements set forth in §§ 1301.72-1301.76 as standards for the physical security controls and operating procedures necessary to prevent diversion.

21 CFR § 1301.71(a)



Suspicious Orders

Non-practitioners of controlled substances


"The registrant shall design and operate a system to disclose to the registrant suspicious orders of controlled substances...Suspicious orders include orders of unusual size, orders deviating substantially from a normal pattern, and orders of unusual frequency."

21 CFR § 1301.74(b)



Prescriptions

A prescription for a controlled substance to be effective must be issued for a Legitimate medical purpose by an individual practitioner acting in the usual course of professional practice.







CDC Guidelines for Prescribing Opioids for Chronic Pain

§ Clinical Reminders:

- Opioids are not first-line or routine therapy for chronic pain
- Establish and measure goals for pain and function
- Discuss benefits and risks and availability of nonopioid therapies with patient



CDC Guidelines for Prescribing Opioids for Chronic Pain

- § Use immediate-release opioids when starting
- § Start low and go slow
- § When opioids are needed for acute pain, prescribe no more than needed
- § Do not prescribe ER/LA opioids for acute pain
- § Follow-up and re-evaluate risk of harm; reduce dose or taper and discontinue if needed



CDC Guidelines for Prescribing Opioids for Chronic Pain

- § Evaluate risk factors for opioid-related harms
- § Check PDMP for higher dosages and prescriptions from other providers
- § Use urine drug testing to identify prescribed substances and undisclosed use
- § Avoid concurrent benzodiazepine and opioid prescribing
- § Arrange treatment for opioid use disorder if needed



Corresponding Responsibility by Pharmacist

The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription.



21 CFR § 1306.04(a)




Corresponding Responsibility by Pharmacist

- § A pharmacist, by law, has a corresponding responsibility to ensure that prescriptions are legitimate.
- § When a prescription is presented by a patient or demanded to be filled for a patient by a doctor's office, a pharmacist is <u>not</u> obligated to fill the prescription!!!





The Last Line of Defense



U.S. Drug Enforcement Administration
Office of Diversion Control



Potential Red Flags

Many customers receiving the same combination of prescriptions; cocktail

Many customers receiving the same strength of controlled substances; no individualized dosing: multiple prescriptions for the strongest dose

Many customers paying cash for their prescriptions

Early refills

Many customers with the same diagnosis codes written on their prescriptions;

Individuals driving long distances to visit physicians and/or to fill prescriptions;



Potential Red Flags continued

Customers coming into the pharmacy in groups, each with the same prescriptions issued by the same physician; and

Customers with prescriptions for controlled substances written by physicians not associated with pain management (i.e., pediatricians, gynecologists, ophthalmologists, etc.).


Overwhelming proportion of prescriptions filled by pharmacy are controlled substances

Pharmacist did not reach out to other pharmacists to determine why they were not filling a particular doctor's prescription

Verification of legitimacy not satisfied by a call to the doctors office



www.nabp.net





Red Flag?

What happens next?

You attempt to resolve...



Resolution is comprised of many factors

- Verification of a valid practitioner DEA number! It is not, however, the end of the pharmacist's duty. Invalid DEA number = Invalid RX
- § Resolution cannot be based solely on patient ID and prescriber verification.
- § You must use your professional judgment, training and experience...we all make mistakes
- § Knowledge and history with the patient
- § Circumstances of prescription presentation
- § Experience with the prescribing practitioner
- § It does not require a call to the practitioner for every CS RX
- § This is not an all-inclusive list...



Who do I call to report a practitioner?

- State Board of Pharmacy, Medicine, Nursing, Dental
- State, County, Local Police
- Ø DEA local office and Tactical Diversion Squad
- Ø Health Department
- ØHHS OIG if Medicare, Medicaid fraud



The DEA Response





Drug Enforcement Administration

360 Degree Strategy





Drug Enforcement Administration

Community Partnerships



- DEA recognizes we cannot arrest our way out of the drug problem – our goal is lasting success in the communities we serve.
- Education and Prevention are key elements for a true 360 Strategy.
- Law enforcement operations provide an opportunity for community empowerment and a jumping off point for education and prevention efforts.



DEA Registrant Initiatives

Distributor Initiative

Educate and inform distributors/manufacturers of their due diligence responsibilities under the CSA by discussing their Suspicious Order Monitoring System, reviewing their ARCOS data for sales and purchases of Schedules II and III controlled substances, and discussing national trends involving the abuse of prescription controlled substances

Briefings to 99 firms with 309 registrations




DEA Registrant Initiatives

Pharmacy Diversion Awareness Conference

This conference is designed to educate pharmacists, pharmacy technicians, and pharmacy loss prevention personnel on ways to address and respond to potential diversion activity

Completed PDACs	<u>Attendance</u>
<u>FY-2011</u>	
1-Cincinnati, OH 9/17-18/11	75
FY-2011 Total Attendance	75
<u>FY-2012</u>	
2-WPB, FL 3/17-18/12	1,192
3-Atlanta, GA 6/2-3/12	328
4-Houston, TX 9/8-9/12	518
5-Long Island, NY 9/15-16/12	391
FY-2012 Total Attendance	2,429
<u>FY-2013</u>	
6-Indianapolis, IN 12/8-9/12	137
7-Albuquerque, NM 3/2-3/13	284
8-Detroit, MI 5/4-5/13	643
9-Chicago, IL 6/22-23/13	321
10-Portland, OR 7/13-14/13	242
11-Baton Rouge, LA 8/3-4/13	259
12A-San Diego, CA 8/16-17/13	353
12B-San Jose, CA 8/18-19/13	434
13-Boston, MA 9/21-22/13	275
FY-2013 Total Attendance	2,948
FY-2014	
14-Louisville, KY 11/16-17/13	149
15-Charlotte, NC 2/8-9/14	513
16-Knoxville,TN 3/22-23/14	246
17-St. Louis, MO 4/5-6/14	224
18-Philadelphia,PA 7/12-13/14	276
19-Denver, CO 8/2-3/14	174
20-SLC, UT 8/23-24/14	355
21-Phoenix, AZ 9/13-14/14	259
FY-2014 Total Attendance	2,196
FY-2015	
22-Las Vegas, NV 2/7-8/15	193
23-Birmingham, AL 3/28-29/15	296
24-Norfolk, VA 5/30-31/15	410
25-Oklahoma City 6/27-28/15	253
26-Milwaukee, WI 7/25-26/15	114
27-Seattle, WA 8/8-8/9/15	210
28-Portland, ME 9/12-9/13/15	94
FY-2015 Total Attendance	1,570
FY-2016	
29-Pittsburgh, PA 12/10-11/15	196
30-Jackson, MS 1/9-10/16	185
31-Charleston, WV 2/27-28/16	245
32-Wilmington, DE 3/19-20/16	111
33-Towson, MD 4/17-4/18/16	442
34-Little Rock, AR 6/11-12-/16	216
35-Minneapolis/St. Paul, MN 7/8-9/16	151
36-Hilton Head, SC 8/15-16/16	157
37-Camp Hill, PA 8/27/16	84
38-New Brunswick, NJ 9/18-19/16	304
39-Fargo, ND 10/2/16	68
40-Washington, DC 11-19-20/16	414
41-Buffalo, NY 12/9-12/10/16	239
Total Attendance To Date	12,030
Total Attenuance to Date	12,030

PDAC MAP



FY-2017 PDACs

42-Honolulu – January 22 & 23, 2017

43-Alaska – February 10, 2017

44-Kansas – March 11 & 12, 2017

45-Puerto Rico – March, 2017 (Date TBD)

46-South Dakota (Possibly combined w/IA & NE) – Spring 2017 (Date TBD)

47-Vermont/New Hampshire – Spring 2017 (Date TBD)

48-Connecticut/Rhode Island – May 2017 (Date TBD)

49-Nebraska – June 2017 (Date TBD)


50-lowa – July 2017 (Date TBD)

51- Idaho/Montana/Wyoming – TBD

37 STATES (incl. the D.C.)

82 PDAC CONFERENCES





* Repeated State



DEA Registrant Initiatives

- § The Federation of State Medical Boards (FSMB) promotes excellence in medical practice, licensure, and regulation on behalf of 70 state medical and osteopathic Boards across the country in their protection of the public
- § DEA and FSMB are currently working on developing strategies to work more effectively and jointly on indiscriminate prescriber investigations in order to facilitate the administrative process to take action against those that are a threat to the public health and welfare quickly, and at the same time not jeopardize a criminal investigation



DEA Registrant Initiatives

"Stakeholders' Challenges and Red Flag Warning Signs Related to Prescribing and Dispensing Controlled Substances"

- § Represents the medical, pharmacist, and supply chain spectrum highlighting the challenges and "red flag" warning signs related to prescribing and dispensing controlled substance prescriptions
- The goal was to provide health care practitioners with an understanding of their shared responsibility to ensure that all controlled substances are prescribed and dispensed for a legitimate medical purpose, as well as to provide guidance on which red flag warning signs warrant further scrutiny
- § NABP along with 10 national associations and 6 major pharmaceutical firms were the coalition of stakeholders of this document.




Scheduled Investigations

- § Increase in the number of DEA registrants that are required to be investigated to ensure compliance with the Controlled Substances Act and its implementing regulations
- § Increase in the frequency of the regulatory investigations
- § Verification investigations of customers and suppliers



Since 2011, Eleven States have Passed Legislation Mandating Prescriber Education





Maine

- § Second State to Mandate Electronic Prescribing
- § Prescribers are required to undergo addiction training every 2 years
- § Set cap on daily strength for opioid prescribing:
 - Acute pain 7 days
 - Chronic pain 30 days
- § To begin January 2017




National Take Back Initiative



10:00 AM - 2:00 PM


National Take Back I-XII Totals:

Total Weight Collected (pounds): 7,202,977 (3601 Tons)





Secure and Responsible Drug Disposal Act of 2010





Ultimate User

Ultimate user means as "a person who has lawfully obtained, and who possesses, a controlled substance for his own use or for the use of a member of his household or for an animal owned by him or a member of his household."

21 USC § 802(27)

Ultimate user methods of destruction prior to Disposal rule:

- ü Disposal in Trash (ONDCP method); or
- ü Flushing (FDA opioids and select CSs)
- ü National Take-back Event (DEA)
- ü Transfer to Law Enforcement
- ü (Police Station Receptacles or local Take-back events)
- ü DEA





Secure and Responsible Drug Disposal Act of 2010

- § CSA amended to provide ultimate users and LTCF with additional methods to dispose of unused, unwanted or expired controlled substance medication in a secure, safe and responsible manner 21 USC § 822(f) & (g)
- § Participation is voluntary21 USC § 822(g)(2)
- § Registrants authorized to collect:
 - Ø Manufacturers
 - Ø Distributors
 - Ø Reverse Distributors
 - Marcotic Treatment Programs
 - ∅ Hospitals/clinics with an on-site pharmacy
 - Ø Retail Pharmacies
 - 21 CFR § 1317.40

Authorized
collectors, as
registrants, are
readily familiar with
the security
procedures and
other requirements
to handle
controlled
substances



Law Enforcement

- § Law Enforcement may continue to conduct take-back events.
- § Any person may partner with Law Enforcement.
- § Law Enforcement shall maintain control and custody of collected substances until secure transfer, storage, or destruction has occurred.
- § Authorized collection receptacles and inner liners "should" be used.


21 CFR § 1317.35 and 1317.65







Collection






Collection

Collection means to receive a controlled substance for the purpose of destruction from an:

- o Ultimate user,
- Person lawfully entitled to dispose of an ultimate user decedent's property, or
- LTCF on behalf of an ultimate user who resides or has resided at the facility.

21 USC § 822(g)(3) & (4) and 21 CFR § 1300.01(b)





Design of Collection Receptacles

- § Securely fastened to a permanent structure.
- § Securely locked, substantially constructed container with permanent outer container and removable inner liner.
- Solution of the second of t
- Solution of the substances of the substances of the substances of the substances.
 Solution of the substance of the
- § Schedule I controlled substances are not permitted to be collected



21 CFR § 1317.75(e)



Collection Receptacle Inner Liner

- ü Waterproof, tamper-evident, and tear-resistant.
- ü Removable and sealable upon removal without emptying or touching contents.
- ü Contents shall not be viewable from the outside when sealed (i.e., can't be transparent).
- ü Size shall be clearly marked on the outside of the liner (e.g., 5-gallon, 10-gallon, etc.).
- ü Outside of liner shall have permanent, unique ID number.



Collection Receptacles

- Ultimate users shall put the substances directly into the collection receptacle.
- Controlled and non-controlled substances may be comingled.
- Ø Collected substances shall not be counted, sorted, inventoried, or otherwise individually handled.
- Ø Registrants shall not dispose of stock or inventory in collection receptacles.

21 CFR § 1317.75(b) and (c)



Collection Receptacle Location

- § Registered location immediate proximity of designated area where controlled substances are stored and at which an employee is present.
 - LTCF located in secure area regularly monitored by LTCF employees.
 - Hospital/clinic located in an area regularly monitored by employees---not in proximity of where emergency or urgent care is provided.
 - NTP located in a room that does not contain any other controlled substances and is securely locked with controlled access.

21 CFR § 1317.75(d)



Mail-Back Program


Requirements of mail-back program

- Only lawfully possessed schedules II-V controlled substances may be collected
- Controlled and non-controlled substances may be collected together
- Ø Must have method of on-site destruction 21 CFR § 1317.70 (b)

DEA Registrant who sells mail-back packages for another registrant is **NOT** required to modify registration as a collector



Registrant Disposal





Registrant Disposal - Inventory

Practitioner & Non-Practitioner may dispose of inventory

- § Prompt on-site destruction
- § Prompt delivery to reverse distributor by common or contract carrier or reverse distributor pick-up
- § Return and recall: Prompt delivery by common or contract carrier or pick-up at the registered location

Practitioner may also request assistance from the SAC Non-Practitioner may also transport by its own means

21 CFR § 1317.05(a) and (b)



DEA Form 41

- § Form 41 shall be used to record the <u>destruction of all controlled</u> <u>substances, including controlled substances acquired from collectors.</u>
 - The Form 41 shall include the names and signatures of the two employees who witnessed the destruction.
 - Exceptions for DEA Form 41:
 - § Destruction of a controlled substance dispensed by a practitioner for immediate administration at the practitioner's registered location, when the substance is not fully exhausted (i.e. wastage) shall be properly recorded in accordance with § 1304.22(c), and such record need not be maintained on a Form 41
 - § Transfers by registrant to a reverse distributor must be recorded in accordance with § 1304.22(c), and such record need not be maintained on a Form 41



Abandoned Controlled Substances

 Circumstances when there is no authorized person to dispose of controlled substances

ØSchool

ØSummer camp

ØHospital


- Return to ultimate user is not feasible
- Options

ØContact law enforcement or DEA

ØDestroy on-site



Pharmaceutical Wastage





Pharmaceutical Wastage

Not subject to 21 CFR Part 1317

- Destruction does not have to be "non-retrievable"
- DEA Form 41 must not be utilized
- § Dispensing must be recorded as a record 21 CFR § 1304.22(c)
- § Clarification memorandum on DEA website at www.deaDiversion.usdoj.gov



Miscellaneous Pharmacy Topics





Multiple Prescriptions Schedule II Controlled Substances

- Individual practitioner may issue multiple prescriptions which authorizes patient to receive 90-day supply of C-II
 - § Each separate prescription is for legitimate medical purpose issued by practitioner acting in usual court of professional practice
 - § Written instructions on each prescription indicating <u>earliest date it can be filled</u>
 - § Doesn't cause undue risk of diversion by patient
 - § Compliance with all other elements of CSA and state laws



Faxed Prescription vs. EPCS

- True electronic prescriptions are transmitted as electronic data files to the pharmacy, whose application imports the data file into its database.
- A system that allows the prescriber to "sign" his/her name does NOT conform to EPCS regulations.
- A facsimile with a written signature is <u>NOT</u> an electronic Rx.

21 CFR § 1306.05(d)



Hospice & LTCF Prescriptions

<u>Schedule II narcotic substances</u> may be transmitted by the practitioner or the practitioner's agent to the dispensing pharmacy by facsimile

- § Practitioner (or agent) must note it is hospice patient
- § Facsimile serves as original written prescription

21 CFR § 1306.11(f), (g) & 1306.13(b)

Schedule III-V prescription

- Written prescription signed by a practitioner, or
- Facsimile of a writtern signed prescription



Distribution by Pharmacy to Practitioner


- Practitioner registered to dispense may distribute a quantity of such substance to another practitioner for general dispensing
 - Purchaser must be registered with DEA
 - Schedule III-V records by purchaser and receiver must conform to 21 CFR § 1304.22(c)
 - Schedule I or II an order form must be used and must conform to 21 CFR § 1305
 - Total number of controlled substances <u>dispensed cannot exceed 5%</u> of total controlled substances dispensed

21 CFR § 1307.11(a)(1)




Repackaging by Pharmacy

- Practitioner can prepare, compound, package, or label in the course of his professional practice 21 CFR § 1300.01(b)
- Pharmacy can **NOT** repackage drugs (ie 100 ct bottle packaged in smaller size bottles) and sell the drugs in the form of a distribution to any DEA Registrant including practitioner office.
- Violation of DEA and FDA regulations



Questions?



Luis.A.Carrion@usdoj.gov